Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027

Despite a recent 4% YTD decline, Eli Lilly (LLY) is poised for further growth, potentially reaching a $1 trillion valuation by 2027, driven by its GLP-1 treatments like Zepbound and Mounjaro. Upcoming catalysts include orforglipron, an oral weight loss drug with promising clinical trial results showing a 15% body weight reduction, and retatrutide, an injectable treatment demonstrating over 24% weight loss in trials; while the healthcare sector faces headwinds, Lilly's 32% sales growth to $45 billion last year, coupled with a more attractive forward P/E of 34 and a PEG ratio of 1.1, suggests the stock is currently undervalued.

Analysis

Eli Lilly (LLY) stands as the world's most valuable healthcare firm, capitalized at over $650 billion, despite its stock experiencing a greater than 4% decline year-to-date. The company's historical growth is significant, with its stock appreciating nearly 400% over the past five years, and sales expanded by 32% in the last year to reach $45 billion, largely fueled by the success of its GLP-1 treatments: Zepbound for weight loss and Mounjaro for diabetes. Key future growth catalysts include orforglipron, an oral drug candidate targeting weight loss and glucose reduction, which has shown approximately 15% body weight loss in trials and could see regulatory approval by next year. Additionally, retatrutide, an injectable treatment, has demonstrated even more substantial efficacy, with patients losing over 24% of body weight in a recent clinical trial. While the broader healthcare sector, as indicated by the Health Care Select Sector SPDR Fund's over 3% decline since January, faces challenges, Eli Lilly's valuation metrics have improved; its trailing price-to-earnings (P/E) ratio is now 60, down from previous highs over 100, its forward P/E is estimated at 34, and its price-to-earnings growth (PEG) ratio is approximately 1.1, suggesting the stock may be attractively valued given its growth outlook. The article suggests these factors could support a trajectory towards a $1 trillion market capitalization by 2027.

Key Decisions for Investors

• Investors should closely monitor the clinical trial progress and subsequent regulatory approval timelines for Eli Lilly's pipeline drugs, particularly orforglipron and retatrutide, as these represent significant near-term growth catalysts.
• Consider the current valuation, with a forward P/E of 34 and a PEG ratio around 1.1, as a potentially favorable entry point, especially given the stock's recent underperformance relative to its strong fundamentals and growth prospects.
• Evaluate Eli Lilly's resilience and growth trajectory against the backdrop of general healthcare sector headwinds, noting its reported 32% sales growth last year as a differentiating factor.